Laboratory of Immunotherapy, Sun Yet-Sen University, Guangzhou, Guangdong, People's Republic of China.
Department of Immunobiology, Yale School of Medicine, Yale University, New Haven, 06511, CT, USA.
Cell Mol Immunol. 2018 Sep;15(9):838-845. doi: 10.1038/cmi.2017.16. Epub 2017 May 8.
Programmed death one homolog (PD-1H) is a cell surface molecule of the B7/CD28 immune modulatory gene family. Although PD-1H has been shown to function as a coinhibitory receptor on T cells to limit naive T-cell activation and proliferation, its role in the regulation of the T-cell response to allergens is unknown. We report here that genetic ablation or blockade of PD-1H drastically promotes pulmonary inflammation with massive accumulation of eosinophils in a mouse model of experimental asthma, indicating a suppressive function of PD-1H in allergic inflammation. The loss of PD-1H led to elevated production of both innate cytokines (IL-6, MCP-1 and TNFα) and Th2 cytokines (IL-5 and IL-13) in the lung, indicating a critical role of PD-1H in suppressing the production of airway inflammatory cytokines. In addition, the loss of PD-1H also impaired the expansion of systemic and pulmonary regulatory T cells during asthma induction. These findings support a critical role of intrinsic PD-1H in the regulation of inflammatory responses to allergens. Finally, we showed that treatment with a PD-1H agonistic monoclonal antibody reduced the severity of asthma, which was accompanied by suppressed lung inflammation. Our findings support PD-1H as a potential target and suggest a possible strategy for the treatment of allergic asthma in humans.
程序性死亡受体 1 同源物(PD-1H)是 B7/CD28 免疫调节基因家族的细胞表面分子。尽管已经表明 PD-1H 作为 T 细胞上的共抑制受体发挥作用,以限制幼稚 T 细胞的活化和增殖,但它在调节 T 细胞对过敏原的反应中的作用尚不清楚。我们在这里报告,在实验性哮喘的小鼠模型中,PD-1H 的遗传缺失或阻断可显著促进肺部炎症,导致嗜酸性粒细胞大量积聚,表明 PD-1H 在过敏性炎症中具有抑制作用。PD-1H 的缺失导致肺部先天细胞因子(IL-6、MCP-1 和 TNFα)和 Th2 细胞因子(IL-5 和 IL-13)的产生均升高,表明 PD-1H 在抑制气道炎症细胞因子的产生中起关键作用。此外,PD-1H 的缺失也损害了哮喘诱导期间系统性和肺调节性 T 细胞的扩增。这些发现支持 PD-1H 在调节对过敏原的炎症反应中具有重要作用。最后,我们表明,使用 PD-1H 激动性单克隆抗体治疗可减轻哮喘的严重程度,同时伴有肺部炎症的抑制。我们的研究结果支持 PD-1H 作为潜在的治疗靶点,并为人类过敏性哮喘的治疗提供了一种可能的策略。